Heterozygosity for hypoxia inducible factor 1a decreases the incidence of thymic lymphomas in a p53 mutant mouse model

Cancer Research

Volumn 69, Issue 7, 2009, Pages 3213-3220

  Bertout, Jessica A ^a,b   Patel, Shetal A ^a,b   Fryer, Benjamin H ^a   Durham, Amy C ^b   Covello, Kelly L ^a   Olive, Kenneth P ^a   Goldschmidt, Michael H ^b   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH1 RECEPTOR; PROTEIN P53; HIF1A PROTEIN, MOUSE; NOTCH1 PROTEIN, MOUSE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DTX1 GENE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE TARGETING; HETEROZYGOSITY; MOUSE; MUTANT; NONHUMAN; NRARP GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMUS LYMPHOMA; TUMOR GENE; AGE; ALLELE; ANIMAL; BIOSYNTHESIS; FEMALE; GENETICS; HETEROZYGOTE; LYMPHOMA; MALE; METABOLISM; MUTATION; THYMOMA; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

AGE FACTORS; ALLELES; ANIMALS; FEMALE; GENES, P53; HETEROZYGOTE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOMA; MALE; MICE; MICE, TRANSGENIC; MUTATION; RECEPTOR, NOTCH1; THYMUS NEOPLASMS;

EID: 66149108432     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4223     Document Type: Article

References (40)

1. Gordan JD, Simon MC Hypoxia-Inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17:71-77
2. Wenger RH, Stiehl DP, Camenisch G Integration of oxygen, signaling at the consensus HRE. Sci STKE 2005; 2005:rel.2.
3. Jain S, Maltepe E, Lu MM, Simon C, Bradfleld CA Expression of ARNT, ARNT2, HIFI α HIF2 α and Ah receptor mRNAs in the developing mouse. Mech Dev 1998;73:117-123
4. Tian. H., McKnight S.L., Russell D.W. Endothelial. PAS domain protein. 1. (EPASl), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
5. Wiesener MS, Jurgensen JS, Rosenberger C, et al. Widespread hypoxia-inducible expression of HTF-2a in distinct cell populations of different organs. FASEB J 2003;17:271-273
6. Covello KL, Kehler J, Yu H, et al HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006;20: 557-570
7. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C., Differential roles of hypoxia-inducible factor lα (HIF-1α) and HIF-2α in hypoxic gene regulation.
8. Gruber M, Hu CJ, Johnson RS, et al Acute postnatal, ablation of Hif-2α results in anemia. Proc Natl Acad Sci USA. 2007;104:2301-2306
9. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1 α is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-4015
10. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, et al. Recruitment of HIF-1α and HTF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an. aggressive phenotype. Cancer Cell 2006:10:413-23
11. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
12. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. Inhibition, of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-246
13. Maranchie JK, Vasselli JR, Riss J, et al The contribution of VHL substrate binding and HIFl-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-255
14. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-I) and HIF-2 In von HIppel-Llndau-associated renal cell carcinoma MoI Cell Biol 2005:25:5675-5686
15. Acker T Dlez-Juan A Aragones J et al. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 2005:8:131-141
16. Liao D Corle C Seagroves TN Johnson RS Hypoxia-inducible factor-la is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007:67:563-572
17. Covello KL, Simon MC, Keith B Targeted replacement of hypoxia-Inducible factor-lα by a hypoxia-inducible factor-2α knock-in allele promotes tumor growth. Cancer Res 2005;65:2277-2286
18. Talks KL Turley H Gatter KC et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000:157: 411-421
19. Olive KP, Tuveson DA, Ruhe ZC, et al Mutant p53 gain, of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-860
20. Wijnhoven SW, Speksnijder EN, Liu X, et al. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res 2007;67:4648-4656
21. Wijnhoven S.W., Zwart E., Speksnijder E.N., et al. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 2005;65: 81.66-73
22. Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65:10280-10288
23. Nacht M, Jacks T V(D)J recombination is not required for the development of lymphoma in p53-deflcient mice. Cell Growth Differ 1998;9:131-138
24. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC HIF-2α promotes hypoxic cell proliferation, by enhancing c-myc transcriptional activity. Cancer Cell 2007:11: 335-347
25. O'Neil J, Calvo J, McKenna K, et al. Activating Notchl mutations in mouse models of T-ALL. Blood 2006:107: 781-785
26. Attardi LD, Jacks T The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sei 1999;55:48-63.
27. Aster JC, Pear WS, Blacklow SC Notch signaling in leukemia. Annu Rev Pathol 2008;3:587-613.
28. Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H The Notch pathway in cancer: differentiation gone awry. Eur J Cancer 2005:41:2620-2629
29. Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005;9:617-628
30. Terzian T, Suh YA, Iwakuma T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-1344
31. Song H, Hollstein M, Xu Y p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007;9:573-580
32. Bassing CH, Suh H, Ferguson DO, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003;114:359-370
33. Ward IM, Difillppantonlo S, Minn K, et al. 53BP1. cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 200525: 10079-10086.
34. Dang CV Kim JW, Gao P, Yustein J The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008;8: 51-56.
35. Gao P, Zhang H, Dinavahi R, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Ce11 2007;12:230-238
36. Pear WS, Aster JCScott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996;183:2283-2291
37. Aster JC, Xu L, Karnell FG, et al. Essential roles for ankyrin repeat and transactivation domains in induction, of T-cell leukemia by notch 1. MoI Cell Biol 2000;20: 7505-7515
38. Bellavia D, Campese AF, Alesse E, et al. Constitutive activation of NF-κB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000;19:3337-3348
39. Sharma VM, Calvo JA, Draheim. KM, et al. Notch1 contributes to mouse T-cell leukemia by directly Inducing the expression, of c-myc. MoI Cell Biol 2006; 26:8022-8031
40. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia Science 2004;306:269-271